Indian drug maker Datsons Labs specializing in manufacturing of anti-malarial drugs has received the proposal to supply the artemesinin-based combination therapies (ACTs) to the Clinton Health Access Initiative  (CHAI), the healthcare project of the Clinton Foundation.

The company will be making a significant deal though there is a minimum pricing that the company will be working on. The volume will be huge because it will be supplied to most of the African countries. In the UNITAID-CHAI malaria treatment project 2015, other big player such as Cipla, Ipca and other Indian players are already on the approved list of the Clinton Health Access Initiative to supply the drugs.

Shares of the company gained Rs 0.6, or 8.03%, to trade at Rs 8.07. The total volume of shares traded was 2,014,368 at the BSE (1.35 p.m., Monday).